Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : Talcum Powder Lawsuit Plaintiffs Claim Unsealed Documents Show Johnson & Johnson Knew of Talc- Asbestos Danger in 1970s, Bernstein Liebhard LLP...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 07:32pm CEST

Talcum Powder Lawsuit Plaintiffs Claim Unsealed Documents Show Johnson & Johnson Knew of Talc- Asbestos Danger in 1970s, Bernstein Liebhard LLP Reports

By a News Reporter-Staff News Editor at Women's Health Weekly -- Plaintiffs pursuing talcum powder lawsuits in Missouri state court claim that newly unsealed documents show that Johnson & Johnson has known since the 1970s that its talc-based powders contained asbestos fibers, which could increase the risk of ovarian cancer in women who used the products for daily feminine hygiene. (Case No. 1522-CC10417, Circuit Court, City of St. Louis, Missouri)

"Our Firm is representing women who allegedly developed ovarian cancer due to Johnson & Johnson's talcum powder products. These documents are of great interest to our clients, and we will continue to monitor the Missouri litigation for any other developments that could impact their claims," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices, drugs and consumer products. The Firm is offering free legal reviews to women who were diagnosed with ovarian cancer that may be associated with Johnson & Johnson'sBaby Powder and Shower-to-Shower products (see also Bernstein Liebhard Llp).

Keywords for this news article include: Talc, Asbestos, Oncology, Gynecology, Legal Issues, Silicic Acid, Women's Health, Silicon Dioxide, Silicon Compounds, Inorganic Chemicals, Magnesium Silicates, Risk and Prevention, Mixed Ovarian Cancer, Bernstein Liebhard Llp.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08:33p JOHNSON & JOHNSON : The Fastest Growing Regions for Dermatological Drug Sales Ar..
08:29p JOHNSON & JOHNSON : Missouri court throws out $72M million verdict in Johnson & ..
05:21p JOHNSON & JOHNSON : Looking back on Black Monday, the stock market crash of 1987
04:30p Genmab Announces Net Sales of DARZALEX for Third Quarter of 2017
04:29p JOHNSON & JOHNSON : and Reports 2017 Third Quarter Results
02:29p ENDOLOGIX, INC. (NASDAQ : ELGX) Files An 8-K Departure of Directors or Certain O..
01:52p JOHNSON & JOHNSON : Earnings Review and Free Research Report: Johnson & Johnson ..
12:51p JOHNSON & JOHNSON : Announces Quarterly Dividend for Fourth Quarter 2017
12:11p JOHNSON & JOHNSON : Medical GmbH to Acquire Surgical Process Institute
10:38a UNITEDHEALTH : Markets summary with a ‘win-win’ deal
More news
News from SeekingAlpha
09:25a Alcobra up 46% premarket on Arcturus/Janssen deal in HBV
07:40a Market Is Not Waiting For Tax Reform - Cramer's Mad Money (10/18/17)
07:31a Johnson & Johnson to acquire Surgical Process Institute
06:56a Johnson & Johnson declares $0.84 dividend
12:18a J&J : Unattractive
Financials ($)
Sales 2017 76 224 M
EBIT 2017 23 484 M
Net income 2017 15 953 M
Debt 2017 16 378 M
Yield 2017 2,38%
P/E ratio 2017 24,13
P/E ratio 2018 19,71
EV / Sales 2017 5,17x
EV / Sales 2018 4,79x
Capitalization 378 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 144 $
Spread / Average Target 2,3%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON22.11%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER10.31%213 372
MERCK AND COMPANY7.88%173 214
AMGEN27.41%135 924